Biomarker response and therapy prediction in renal denervation therapy - the role of MR-proadrenomedullin in a multicenter approach
Standard
Biomarker response and therapy prediction in renal denervation therapy - the role of MR-proadrenomedullin in a multicenter approach. / Neumann, Johannes Tobias; Schwerg, Marius; Dörr, Oliver; Mortensen, Kai; Franzen, Klaas; Zeller, Tanja; Ojeda, Francisco; Blankenberg, Stefan; Hamm, Christian; Nef, Holger; Stangl, Verena; Möckel, Martin; Sydow, Karsten.
in: BIOMARKERS, Jahrgang 22, Nr. 3-4, 07.05.2016, S. 225-231.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Biomarker response and therapy prediction in renal denervation therapy - the role of MR-proadrenomedullin in a multicenter approach
AU - Neumann, Johannes Tobias
AU - Schwerg, Marius
AU - Dörr, Oliver
AU - Mortensen, Kai
AU - Franzen, Klaas
AU - Zeller, Tanja
AU - Ojeda, Francisco
AU - Blankenberg, Stefan
AU - Hamm, Christian
AU - Nef, Holger
AU - Stangl, Verena
AU - Möckel, Martin
AU - Sydow, Karsten
PY - 2016/5/7
Y1 - 2016/5/7
N2 - BACKGROUND: Renal denervation has been proposed as a therapeutic option in patients with resistant hypertension. Circulating blood borne biomarkers might be helpful to identify individuals responding to RDN therapy. MR-proADM is a strong prognostic marker in patients with cardiovascular disease. The aim of this multicenter study was to evaluate the effect of RDN on MR-proADM concentrations.METHODS AND RESULTS: We measured MR-proADM, BNP, and MR-proANP in 110 patients before and after RDN in a multicenter setting. All patients were followed up after 1 and 6 months by office and ambulatory blood pressure (BP) measurements. The mean office BP decreased from 165/89 to 152/87 mmHg 6 months after RDN (systolic: p < 0.001; diastolic: ns), the responder-rate was 74%. Intriguingly MR-proADM concentrations increased from 0.66 to 0.69 nmol/L (p < 0.001) and were significantly associated with reduction of systolic office BP after 6 months in multivariate analyses (coefficient -0.0018, p < 0.001). In therapy-responders MR-proADM concentrations showed a significantly higher increase over time (coefficient 0.0105, p < 0.05), as compared to non-responders. There were no significant differences in BP change for individuals with low and high baseline MR-proADM (BP-Delta low MR-proADM -23/-4 mmHg vs. high MR-proADM -24/-5 mmHg). The natriuretic biomarkers BNP and MR-proANP did not change significantly after 6 months. Biomarkers at baseline were not able to predict for therapy-responder.CONCLUSION: In patients undergoing RDN, baseline measurements of various biomarkers had no prognostic use for therapy success in this short time follow-up period in a multicenter approach. Intriguingly, MR-proADM showed a significant association with BP reduction after 6 months.
AB - BACKGROUND: Renal denervation has been proposed as a therapeutic option in patients with resistant hypertension. Circulating blood borne biomarkers might be helpful to identify individuals responding to RDN therapy. MR-proADM is a strong prognostic marker in patients with cardiovascular disease. The aim of this multicenter study was to evaluate the effect of RDN on MR-proADM concentrations.METHODS AND RESULTS: We measured MR-proADM, BNP, and MR-proANP in 110 patients before and after RDN in a multicenter setting. All patients were followed up after 1 and 6 months by office and ambulatory blood pressure (BP) measurements. The mean office BP decreased from 165/89 to 152/87 mmHg 6 months after RDN (systolic: p < 0.001; diastolic: ns), the responder-rate was 74%. Intriguingly MR-proADM concentrations increased from 0.66 to 0.69 nmol/L (p < 0.001) and were significantly associated with reduction of systolic office BP after 6 months in multivariate analyses (coefficient -0.0018, p < 0.001). In therapy-responders MR-proADM concentrations showed a significantly higher increase over time (coefficient 0.0105, p < 0.05), as compared to non-responders. There were no significant differences in BP change for individuals with low and high baseline MR-proADM (BP-Delta low MR-proADM -23/-4 mmHg vs. high MR-proADM -24/-5 mmHg). The natriuretic biomarkers BNP and MR-proANP did not change significantly after 6 months. Biomarkers at baseline were not able to predict for therapy-responder.CONCLUSION: In patients undergoing RDN, baseline measurements of various biomarkers had no prognostic use for therapy success in this short time follow-up period in a multicenter approach. Intriguingly, MR-proADM showed a significant association with BP reduction after 6 months.
KW - Adrenomedullin/physiology
KW - Aged
KW - Biomarkers/blood
KW - Blood Pressure
KW - Denervation
KW - Female
KW - Follow-Up Studies
KW - Humans
KW - Hypertension/therapy
KW - Kidney/innervation
KW - Male
KW - Middle Aged
KW - Natriuretic Peptide, Brain/blood
KW - Prognosis
KW - Protein Precursors/physiology
KW - Time Factors
KW - Treatment Outcome
U2 - 10.3109/1354750X.2016.1172112
DO - 10.3109/1354750X.2016.1172112
M3 - SCORING: Journal article
C2 - 27153479
VL - 22
SP - 225
EP - 231
JO - BIOMARKERS
JF - BIOMARKERS
SN - 1354-750X
IS - 3-4
ER -